Get the Stockscreener App
4.27
5.17%
0.21
Foghorn Therapeutics Inc stock is traded at $4.27, with a volume of 4,644.
It is up +5.17% in the last 24 hours and down -17.73% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.06
Open:
$4.19
24h Volume:
4,644
Relative Volume:
0.04
Market Cap:
$241.38M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.8248
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
-5.74%
1M Performance:
-17.73%
6M Performance:
+23.77%
1Y Performance:
-44.04%
1-Day Range:
$4.12
$4.27
1-Week Range:
$4.0207
$4.8398
52-Week Range:
$2.9448
$9.70
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.27 | 229.51M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.29 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.94 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Can trapped investors hope for a rebound in Foghorn Therapeutics Inc.2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Has Foghorn Therapeutics Inc. formed a bullish divergenceQuarterly Portfolio Report & Expert Curated Trade Setups - newser.com
What does recent volatility data suggest for Foghorn Therapeutics Inc.Trade Exit Summary & AI Powered Buy/Sell Recommendations - newser.com
Why Foghorn Therapeutics Inc. stock is rated strong buyTrade Volume Report & Weekly Return Optimization Alerts - newser.com
What institutional flow reveals about Foghorn Therapeutics Inc.Weekly Gains Report & Weekly Return Optimization Alerts - newser.com
Foghorn Therapeutics Inc. stock daily chart insightsGold Moves & AI Forecast for Swing Trade Picks - newser.com
Multi asset correlation models including Foghorn Therapeutics Inc.2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
Will Foghorn Therapeutics Inc. stock go up soonQuarterly Profit Review & Long-Term Capital Growth Strategies - newser.com
Published on: 2025-10-09 05:14:43 - newser.com
Foghorn Therapeutics (NASDAQ:FHTX) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Why Foghorn Therapeutics Inc. stock is seen as undervaluedEntry Point & Safe Entry Zone Tips - newser.com
Using Ichimoku Cloud for Foghorn Therapeutics Inc. technicalsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Chart based exit strategy for Foghorn Therapeutics Inc.Market Risk Report & Verified Technical Trade Signals - newser.com
Detecting price anomalies in Foghorn Therapeutics Inc. with AIOil Prices & Free Technical Pattern Based Buy Signals - newser.com
How to monitor Foghorn Therapeutics Inc. with trend dashboardsMarket Performance Recap & Consistent Profit Alerts - newser.com
Is Foghorn Therapeutics Inc a good long term investmentInsider Trading Compliance & Free High Velocity Capital Growth - earlytimes.in
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):